Common Blood Pressure Drug Recalled Nationwide, FDA Says
The FDA says Novartis recalled one lot of Diovan (valsartan) due to failed dissolution specifications, meaning tablets may not dissolve correctly. The affected product is 160 mg, 90-count bottles, lot AV5913C, exp. June 2027. The recall began Aug. 4 and was later classified Class II. Manufacturing was by Patheon Manufacturing Services.
How this was made
The 30-second read
Why it matters
A Class II recall implies temporary or medically reversible adverse health consequences are possible, but serious adverse outcomes are considered remote. Traders may monitor whether the recall expands beyond the named lot, whether regulators issue additional actions, and whether Novartis discloses any sales or cost impact.
Market read
This is a concrete FDA regulatory action tied to a specific Novartis product lot, which can drive short-term risk repricing in pharma quality-control and supply reliability.
What to watch
The article does not quantify affected units or potential replacement supply, and it does not mention any patient harm, which are key drivers of how much the market reprices the recall risk.
Background
The FDA notice describes a nationwide Class II recall for a specific Diovan (valsartan) lot, citing failed dissolution specifications and failed impurity/degradation specification in a tested batch.
Ticker impact
FDA classified a nationwide recall of one lot of Diovan (valsartan) due to failed dissolution specifications, impacting Novartis’ distributed product.
Moderate downside bias for NVS on recall headlines, with magnitude likely limited unless additional lots, broader product issues, or financial guidance impacts emerge.
The article specifies an FDA Class II recall for a defined Diovan lot and cites manufacturing and distribution by Novartis, but provides no quantity, cost estimate, or guidance impact.
Market effects
Highlights ongoing quality and dissolution/impurity specification compliance risk for large generic/brand manufacturers and contract manufacturers.
Primarily US-focused FDA action, but can affect global sentiment toward valsartan/ARB supply chains.
Could raise scrutiny of valsartan/ARB manufacturing processes across markets if additional recalls follow.
Counterpoint
If the recall scope remains confined to one lot and no broader manufacturing failure is found, the financial impact may be small and the market may fade the headline quickly.
Key entities
- companyNovartis Pharmaceuticals Corporation
Subject of the FDA recall notice for Diovan (valsartan) distribution.
- drugDiovan (valsartan)
Valsartan brand recalled for failed dissolution specifications in one lot.
- regulatorFood and Drug Administration (FDA)
Classified the recall as Class II and issued the recall notice.
- manufacturerPatheon Manufacturing Services LLC
Manufactured the recalled Diovan tablets.
